Biomarkers of rheumatoid arthritis: Recent progress

Expert Opinion on Medical Diagnostics

Volumn 4, Issue 4, 2010, Pages 293-305

  Wu, Tianfu ^a   Sajitharan, Deena ^a   Mohan, Chandra ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Biomarkers; Diagnostics; Proteomics; Rheumatoid arthritis

Indexed keywords

ACUTE PHASE PROTEIN; ANTIPERINUCLEAR FACTOR; AUTOANTIBODY; BIOLOGICAL MARKER; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; KERATIN ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RANTES; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY TITER; B LYMPHOCYTE; BONE MARROW CELL; DIAGNOSTIC PROCEDURE; GENETIC MARKER; HUMAN; METABOLOMICS; NONHUMAN; PATHOGENESIS; PROGNOSIS; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM;

EID: 77953925833     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2010.492828     Document Type: Review

References (114)

1. Combe B, Benessiano J, Berenbaum F, et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74(5):440-445
2. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43(1):155-163
3. Visser H. Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19(1):55-72
4. Visser H, Gelinck LB, Kampfraath AH, et al. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 1996;55(3):157-161
5. Vittecoq O, Pouplin S, Krzanowska K, et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 2003;42(8):939-946
6. Lemm G, Ruschen S, Warnatz H. An ELISA for IgA-IgG and IgM-RF measurement. II. RF in several disease and control groups and under gold therapy in RA. Scand J Rheumatol Suppl 1988;75:256-260
7. Bobbio-Pallavicini F, Caporali R, Alpini C, et al. Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. Ann NY Acad Sci 2007;1109:287-295
8. Masi AT, Maldonado-Cocco JA, Kaplan SB, et al. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome. Semin Arthritis Rheum 1976;4(4):299-326
9. Edwards JC, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 1998;37(2):126-130
10. Tighe H, Chen PP, Tucker R, et al. Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice. J Exp Med 1993;177(1):109-118
11. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146(11):797-808
12. Skogh T. Does a positive anti-CCP test identify a distinct arthritis entity? Arthritis Res Ther 2005;7(6):230-232
13. Zendman AJ, Vossenaar ER, Van Venrooij WJ. Autoantibodies to citrullinated (poly)peptides: a key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity 2004;37(4):295-299
14. Van Venrooij WJ, Zendman AJ, Pruijn GJ. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006;6(1):37-41
15. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65(7):845-851
16. Riedemann JP, Munoz S, Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis-a systematic review. Clin Exp Rheumatol 2005;23(5 Suppl 39):S69-76
17. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 1964;23:302-305
18. Young BJ, Mallya RK, Leslie RD, et al. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979;2(6182):97-99
19. Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994;21(6):1027-1033
20. Schellekens GA, de Jong BA, Van Den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101(1):273-281
21. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001;166(6):4177-4184
22. Takizawa Y, Suzuki A, Sawada T, et al. Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 2006;65(8):1013-1020
23. Kinloch A, Tatzer V, Wait R, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7(6):R1421-9
24. Okazaki Y, Suzuki A, Sawada T, et al. Identification of citrullinated eukaryotic translation initiation factor 4G1 as novel autoantigen in rheumatoid arthritis. Biochem Biophys Res Commun 2006;341(1):94-100
25. Koivula MK, Aman S, Karjalainen A, et al. Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis? Ann Rheum Dis 2005;64(10):1443-1450 (Pubitemid 41623855)
26. Raza K, Breese M, Nightingale P, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005;32(2):231-238
27. Van Venrooij WJ, Van Beers JJ, Pruijn GJ. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann NY Acad Sci 2008;1143:268-285
28. Correia ML, Carvalho S, Fortuna J, Pereira MH. Comparison of three anti-CCP antibody tests and rheumatoid factor in RA and control patients. Clin Rev Allergy Immunol 2008;34(1):21-25
29. Hui L, Wuqi S, Yang L, et al. Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity. Clin Rheumatol 2010;29(4):413-417
30. Yamane T, Hashiramoto A, Tanaka Y, et al. Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/ rheumatoid factor. J Rheumatol 2008;35(3):414-420
31. Aho K, Palosuo T, Niemela N, Takala J. Rheumatoid factor seroconversions in relation to clinical rheumatoid arthritis. Ann Clin Res 1985;17(1):15-18
32. Aho K, Heliovaara M, Maatela J, et al. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 1991;18(9):1282-1284
33. Kurki P, Aho K, Palosuo T, Heliovaara M. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992;35(8):914-917
34. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48(10):2741-2749
35. Nielen MM, Van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50(2):380-386
36. de Vries RR, Huizinga TW, Toes RE. Redefining the HLA and RA association: to be or not to be anti-CCP positive. J Autoimmun 2005;25(Suppl):21-25
37. Verpoort KN, Van Gaalen FA, Van Der Helm-van Mil AH, et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 2005;52(10):3058-3062
38. Irigoyen P, Lee AT, Wener MH, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005;52(12):3813-3818
39. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30(11):1205-1213
40. Du Montcel ST, Michou L, Petit-Teixeira E, et al. New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum 2005;52(4):1063-1068
41. Berglin E, Padyukov L, Sundin U, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004;6(4):R303-8
42. Van Gaalen FA, Van Aken J, Huizinga TW, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004;50(7):2113-2121
43. Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64(2):196-201
44. Snir O, Widhe M, Hermansson M, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010;62(1):44-52
45. Wesoly J, Van Der Helm-van Mil AH, Toes RE, et al. Association of the PTPN22 C1858T single-nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort. Arthritis Rheum 2005;52(9):2948-2950
46. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther 2006;8(1):R10:1-6
47. Kokkonen H, Johansson M, Innala L, et al. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther 2007;9(3):R56:1-7
48. Feitsma AL, Toes RE, Begovich AB, et al. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients. Rheumatology (Oxford) 2007;46(7):1092-1095
49. Orozco G, Pascual-Salcedo D, Lopez-Nevot MA, et al. Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis. Rheumatology (Oxford) 2008;47(2):138-141
50. Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67(2):212-217
51. Ronnelid J, Wick MC, Lampa J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64(12):1744-1749
52. Turesson C, Jacobsson LT, Sturfelt G, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007;66(1):59-64 (Pubitemid 46044861)
53. Bukhari M, Thomson W, Naseem H, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007;56(9):2929-2935
54. Sanmarti R, Gomez-Centeno A, Ercilla G, et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 2007;26(7):1111-1118
55. Machold KP, Stamm TA, Nell VP, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007;46(2):342-349
56. Van Der Helm-van Mil AH, Verpoort KN, le Cessie S, et al. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007;56(2):425-432
57. Van Oosterhout M, Bajema I, Levarht EW, et al. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum 2008;58(1):53-60
58. Lopez-Longo FJ, Oliver-Minarro D, de La Torre I, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009;61(4):419-424
59. Mikuls TR, O'Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004;50(12):3776-3782
60. Braun-Moscovici Y, Markovits D, Zinder O, et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006;33(3):497-500
61. Semmler M, Seeck U, Neustadt B, et al. No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis. Clin Rheumatol 2007;26(9):1499-1504
62. Blass S, Union A, Raymackers J, et al. The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum 2001;44(4):761-771
63. Cordonnier C, Meyer O, Palazzo E, et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996;35(7):620-624
64. Graudal NA, Svenson M, Tarp U, et al. Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome. Ann Rheum Dis 2002;61(7):598-602
65. Saulot V, Vittecoq O, Charlionet R, et al. Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum 2002;46(5):1196-1201
66. Newkirk MM, Goldbach-Mansky R, Lee J, et al. Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res Ther 2003;5(2):R82-90
67. Clague RB, Morgan K, Reynolds I, Williams HJ. The prevalence of serum IgG antibodies to type II collagen in American patients with rheumatoid arthritis. Br J Rheumatol 1994;33(4):336-338
68. Morgan K, Clague RB, Collins I, et al. Incidence of antibodies to native and denatured cartilage collagens (types II, IX, and XI) and to type I collagen in rheumatoid arthritis. Ann Rheum Dis 1987;46(12):902-907
69. Clague RB, Moore LJ. IgG and IgM antibody to native type II collagen in rheumatoid arthritis serum and synovial fluid. Evidence for the presence of collagen-anticollagen immune complexes in synovial fluid. Arthritis Rheum 1984;27(12):1370-1377
70. Despres N, Talbot G, Plouffe B, et al. Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J Clin Invest 1995;95(4):1891-1896
71. Mimori T, Suganuma K, Tanami Y, et al. Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc Natl Acad Sci USA 1995;92(16):7267-7271
72. Mewar D, Wilson AG. Autoantibodies in rheumatoid arthritis: a review. Biomed Pharmacother 2006;60(10):648-655
73. Mewar D, Moore DJ, Young-Min S, et al. Antiferritin antibodies discovered by phage display expression cloning are associated with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2005;52(12):3868-3872
74. Goeb V, Thomas-L'Otellier M, Daveau R, et al. Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther 2009;11(2):R38:1-14
75. Prieur AM, Roux-Lombard P, Dayer JM. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rhum Engl Ed 1996;63(3):163-170
76. Knudsen LS, Hetland ML, Johansen JS, et al. Changes in plasma IL-6, plasma VEGF and serum YKL-40 during treatment with etanercept and methotrexate or etanercept alone in patients with active rheumatoid arthritis despite methotrexate therapy. Biomark Insights 2009;4:91-95
77. Patel DD, Koopmann W, Imai T, et al. Chemokines have diverse abilities to form solid phase gradients. Clin Immunol 2001;99(1):43-52
78. Garcia-Vicuna R, Gomez-Gaviro MV, Dominguez-Luis MJ, et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum 2004;50(12):3866-3877
79. Katschke KJ Jr, Rottman JB, Ruth JH, et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001;44(5):1022-1032
80. Kanbe K, Takagishi K, Chen Q. Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. Arthritis Rheum 2002;46(1):130-137
81. Hueber W, Robinson WH. Proteomic biomarkers for autoimmune disease. Proteomics 2006;6(14):4100-4105
82. Kokkonen H, Soderstrom I, Rocklov J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010;62(2):383-391
83. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43(1):38-47
84. Gerlag DM, Haringman JJ, Smeets TJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50(12):3783-3791
85. Wijbrandts CA, Vergunst CE, Haringman JJ, et al. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007;56(11):3869-3871
86. Walsh CA, Fearon U, FitzGerald O, et al. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy. Clin Exp Rheumatol 2008;26(4):656-658
87. Teng YK, Levarht EW, Hashemi M, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007;56(12):3909-3918
88. Teng YK, Levarht EW, Toes RE, et al. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 2009;68(6):1011-1016
89. Ogdie A, Li J, Dai L, et al. Identification of broadly discriminatory tissue biomarkers of synovitis with binary and multicategory receiver operating characteristic analysis. Biomarkers 2010;15(2):183-190
90. Blaschke S, Viereck V, Schwarz G, et al. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol 2009;38(4):235-239
91. Stuhlmuller B, Haupl T, Hernandez MM, et al. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther 2010;87(3):311-321
92. Emery P, McInnes IB, Van Vollenhoven R, Kraan MC. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008;47(4):392-398
93. Geusens PP, Landewe RB, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006;54(6):1772-1777
94. Syversen SW, Goll GL, Van Der Heijde D, et al. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 2009;36(2):266-272
95. Landewe R, Geusens P, Boers M, et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004;50(5):1390-1399
96. Crnkic M, Mansson B, Larsson L, et al. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 2003;5(4):R181-5
97. Morozzi G, Fabbroni M, Bellisai F, et al. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol 2007;26(8):1335-1338
98. Mullan RH, Matthews C, Bresnihan B, et al. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum 2007;56(9):2919-2928
99. Carlton VE, Hu X, Chokkalingam AP, et al. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am J Hum Genet 2005;77(4):567-581
100. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357(10):977-986
101. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med 2007;357(12):1199-1209
102. McClure A, Lunt M, Eyre S, et al. Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. Rheumatology (Oxford) 2009;48(11):1369-1374
103. Robinson WH, DiGennaro C, Hueber W, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002;8(3):295-301
104. Auger I, Balandraud N, Rak J, et al. New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis 2009;68(4):591-594
105. Roth EB, Stenberg P, Book C, Sjoberg K. Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis-new pathways to epitope spreading. Clin Exp Rheumatol 2006;24(1):12-18
106. Matsuo K, Xiang Y, Nakamura H, et al. Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res Ther 2006;8(6):R175:1-13
107. Niwa M, Fukuoka K, Fujimoto T, Maruyama IN. Efficient isolation of cDNA clones encoding rheumatoid arthritis autoantigens by lambda phage surface display. J Biotechnol 2004;114(1-2):55-58
108. Somers K, Stinissen P, Somers V. Optimization of high-throughput autoantibody profiling for the discovery of novel antigenic targets in rheumatoid arthritis. Ann NY Acad Sci 2009;1173:92-102
109. Maciejewska-Rodrigues H, Al-Shamisi M, Hemmatazad H, et al. Functional autoantibodies against serpin E2 in rheumatoid arthritis. Arthritis Rheum 2010;62(1):93-104
110. Liao H, Wu J, Kuhn E, et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum 2004;50(12):3792-3803
111. Sinz A, Bantscheff M, Mikkat S, et al. Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis 2002;23(19):3445-3456
112. Trocme C, Marotte H, Baillet A, et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009;68(8):1328-1333
113. Kamphorst JJ, Van Der Heijden R, DeGroot J, et al. Profiling of endogenous peptides in human synovial fluid by NanoLC-MS: method validation and peptide identification. J Proteome Res 2007;6(11):4388-4396
114. Weljie AM, Dowlatabadi R, Miller BJ, et al. An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J Proteome Res 2007;6(9):3456-3464